Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 144 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]
2. Cita con resumen
Anónimo. Crisaborole (Eucrisa) for atopic dermatitis. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:34-5. [Ref.ID 101487]
3. Cita con resumen
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M, SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335-48. [Ref.ID 101031]
5. Cita con resumen
Anónimo. FDA grants priority review to atopic dermatitis drug. DIA Daily 2016:4. [Ref.ID 100760]
6. Cita con resumen
Anónimo. Pfizer to acquire Anacor Pharmaceuticals for $5.2 billion. DIA Daily 2016:1. [Ref.ID 100275]
7.
Stein SL, Cifu AS. Management of atopic dermatitis. JAMA 2016;315:1510-1. [Ref.ID 100229]
8.Tiene citas relacionadas Cita con resumen
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. [Ref.ID 99988]
9.Tiene citas relacionadas
Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet 2016;387:4-5. [Ref.ID 99987]
10. Cita con resumen
Anónimo. Ustekinumab (Stelara): risk of exfoliative dermatitis. Drug Safety Update 2015;8:2. [Ref.ID 98836]
11. Cita con resumen
Anónimo. Ziprasidone (marketed as Geodon and generics): Drug Safety Communication - Rare but potentially fatal skin reactions. U.S. Food and Drug Administration 2014:11 de diciembre. [Ref.ID 98379]
12.Tiene citas relacionadas Cita con resumen
Rassi A, Rassi Jr A. Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med 2014;371:965. [Ref.ID 97979]
13. Cita con resumen
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9. [Ref.ID 97809]
14.Tiene citas relacionadas
Albajar-Viñas P, Días JCP. Adavancing the treatment for Chagas' disease. N Engl J Med 2014;370:1942-3. [Ref.ID 97607]
15.Tiene citas relacionadas Cita con resumen
Molina I, Gómez J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A. Randomized trial of posaconazole and benznidazole for chronic Chaga's disease. N Engl J Med 2014;370:1899-908. [Ref.ID 97606]
16. Cita con resumen
Carlos G, Uribe P, Fernández-Peñas PF. Rational use of topical corticosteroids. Australian Prescriber 2013;36:158-61. [Ref.ID 96317]
17. Cita con resumen
Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]
18.Tiene citas relacionadas Cita con resumen
Gold R, Glovannoni G, Selmaj KH, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, for the SELECT study investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75. [Ref.ID 95716]
19.Tiene citas relacionadas
Saldha S, Calabresi PA. Anti-interleukin-2 receptor alpha for multiple sclerosis?. Lancet 2013;381:2141-3. [Ref.ID 95708]
20. Cita con resumen
Anónimo. Ipilimumab: severe immunemediated reactions. United States of America. WHO Drug Information 2011;25:108. [Ref.ID 90822]
Seleccionar todas
 
 1 a 20 de 144 siguiente >>